Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Vu H Duong,Tibor Kovacsovics,Uma Borate,Matthew C Foster,James M Foran,Nyla A Heerema,Wendy Stock,Rebecca L Olin,Abigail B Shoben,Maria R Baer,Mona Stefanos,Amy Burd,Alice S Mims,John C Byrd,Eytan M Stein,Franchesca Druggan,Gary J Schiller,Christopher R Cogle,Ross L Levine,Amy S Ruppert,Tara L Lin,Sonja Marcus,Robert L Redner,Prapti A Patel,Leonard Rosenberg,Mark R Litzow,Theophilus J Gana ,Martha Arellano ,Brian J Druker ,Timothy Chen ,Jo‐Anne Vergilio ,Ashley Owen Yocum ,Zeina Al‐Mansour ,Ronan T Swords ,Robert H Collins ,William Blum ,Michael Boyiadzis

doi:10.1182/blood-2021-151234

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Vu H Duong, Tibor Kovacsovics + Show 35 more

Open Access

https://doi.org/10.1182/blood-2021-151234

Copy DOI

#Equity Holder In Publicly-traded Company #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Full Text